구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Abatacept |
Overview Company | Novartis Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | Rheumatoid Arthritis |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | novel therapies during periods before long-term safety data become available |
Positioning Known limitation | bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model |
MoA Mechanism | CAR-T therapy induced profound, durable responses in extremely severe patients with seropositive PIRR |
MoA Biomarker | biomarker-derived score, to capture and predict the course of active lupus nephritis (LN) in adult patients |
PK/PD Half-life | 14.3 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | interstitial lung disease: a review of mechanisms and clinical evidence |
Toxicology CRS | grade 4 |
Clinical Safety signal | interstitial lung disease: a review of mechanisms and clinical evidence |
Clinical Result source | ClinicalTrials.gov NCT00124982 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00124982 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Abatacept |
Overview Company | Novartis Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | Rheumatoid Arthritis |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | novel therapies during periods before long-term safety data become available |
Positioning Known limitation | bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model |
MoA Mechanism | CAR-T therapy induced profound, durable responses in extremely severe patients with seropositive PIRR |
MoA Biomarker | biomarker-derived score, to capture and predict the course of active lupus nephritis (LN) in adult patients |
PK/PD Half-life | 14.3 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | interstitial lung disease: a review of mechanisms and clinical evidence |
Toxicology CRS | grade 4 |
Clinical Safety signal | interstitial lung disease: a review of mechanisms and clinical evidence |
Clinical Result source | ClinicalTrials.gov NCT00124982 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00124982 |
추천 비교
추천 비교